Delving into the Latest Updates on Patheon Development Services, Inc. with Synapse

Overview

Tags

Congenital Disorders

Immune System Diseases

Hemic and Lymphatic Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Infectious Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

ITK(Tyrosine-protein kinase ITK/TSK)	1

The primary objectives of this study are to determine the safety and tolerability profile of CPI-818 at escalating dose levels; to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of CPI-818 to select the expansion cohort dose (ECD); and to evaluate the safety and tolerability of CPI-818 in selected R/R T-cell lymphoma subjects.

Start Date17 Dec 2021

Sponsor / Collaborator

Corvus Pharmaceuticals, Inc.

[+2]

CTR20212109 / TerminatedPhase 1

ZN-d5单药用于中国非霍奇金淋巴瘤受试者的I期剂量递增研究

[Translation] A Phase I Dose-Escalation Study of ZN-d5 Monotherapy in Chinese Non-Hodgkin's Lymphoma Subjects

？评估ZN-d5在NHL受试者中的安全性和耐受性？确定NHL受试者的MTD和/或RP2D ？确定ZN-d5在NHL受试者中的PK特征？评估ZN-d5在HNL受试者中的临床活性

[Translation]

? Evaluate the safety and tolerability of ZN-d5 in NHL subjects ? Determine the MTD and/or RP2D in NHL subjects ? Determine the PK characteristics of ZN-d5 in NHL subjects ? Evaluate the clinical activity of ZN-d5 in HNL subjects

Start Date29 Sep 2021

Sponsor / Collaborator

Zentera Therapeutics (Shanghai) Co., Ltd.

[+2]

CTR20210533 / CompletedPhase 1

评价在健康受试者中伊曲康唑和利福平对ASC40药代动力学影响的I期开放、药物-药物相互作用研究

[Translation] A Phase I Open-label, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole and Rifampicin on the Pharmacokinetics of ASC40 in Healthy Subjects

评估伊曲康唑（一种细胞色素P450 3A(CYP3A)的强抑制剂）在健康志愿者中对ASC40的药代动力学的影响；评估利福平（CYP3A的强诱导剂）在健康志愿者中对ASC40的药代动力学的影响；评估在健康志愿者中使用伊曲康唑和利福平时ASC40的安全性和耐受性。

[Translation]

To evaluate the effect of itraconazole, a strong inhibitor of cytochrome P450 3A (CYP3A), on the pharmacokinetics of ASC40 in healthy volunteers; to evaluate the effect of rifampicin, a strong inducer of CYP3A, on the pharmacokinetics of ASC40 in healthy volunteers; and to evaluate the safety and tolerability of ASC40 when itraconazole and rifampicin are used in healthy volunteers.

Start Date30 Mar 2021

Sponsor / Collaborator

Patheon Development Services, Inc.

[+2]

100 Clinical Results associated with Patheon Development Services, Inc.

Login to view more data

0 Patents (Medical) associated with Patheon Development Services, Inc.

Login to view more data

100 Deals associated with Patheon Development Services, Inc.

Login to view more data

100 Translational Medicine associated with Patheon Development Services, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Soquelitinib ( ITK )	T-Cell Lymphoma More	Phase 1
Tigozertinib ( EGFR C797S x EGFR L858R x EGFR T790M x EGFR-Ex19del )	EGFR positive non-small cell lung cancer More	Suspended
Asaretoclax ( Bcl-2 )	Non-Hodgkin Lymphoma More	Discontinued
Denifanstat ( FASN )	Nonalcoholic Steatohepatitis More	Pending